Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.68 |
| ▸ | CTSD | P07339 | 2/20 | 0.65 |
| ▸ | APP | P05067 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008359 | 0.81 | BACE1 (1.00) | BACE1CTSDAPPKMT2AMEN1 | |
| SCHEMBL3017322 | 0.81 | BACE1 (1.00) | BACE1CTSDAPPKMT2AMEN1 | |
| SCHEMBL3020997 | 0.81 | BACE1 (1.00) | BACE1CTSDAPPHPGDALDH1A1 | |
| SCHEMBL3013661 | 0.79 | BACE1 (1.00) | BACE1CTSDAPPHPGDKMT2A | |
| SCHEMBL3020820 | 0.78 | BACE1 (1.00) | BACE1CTSDAPPHPGDRAB9A | |
| SCHEMBL3014874 | 0.78 | BACE1 (1.00) | BACE1CTSDAPP | |
| SCHEMBL3014975 | 0.78 | BACE1 (1.00) | BACE1CTSDAPP | |
| SCHEMBL29687327 | 0.74 | HPGD (1.00) | HPGDKMT2AMEN1ATML3MBTL1 | |
| SCHEMBL30678539 | 0.74 | HPGD (1.00) | HPGDKMT2AMEN1ATML3MBTL1 | |
| SCHEMBL743611 | 0.74 | HPGD (1.00) | HPGDKMT2AMEN1ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204245-A1 | Amino-pyridines As Inhibitors Of Beta-secretase | WYETH LLC (US) | 2010-08-12 | — | — | US | claimed |
| US-20060173049-A1 | enzyme inhibitors such as 6-{2-(2-Chloro-phenyl)-5-[4-(pyrimidin-2-yloxy)-phenyl]pyrrol-1-ylmethyl}-pyridin-2-ylamine, used to treat beta-amyloid deposits and neurofibrillary tangles; Alzheimer's disease | WYETH (US) | 2006-08-03 | — | — | US | claimed |
| US-20100204245-A1 | Amino-pyridines As Inhibitors Of Beta-secretase | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7732457-B2 | Amino-pyridines as inhibitors of β-secretase | WYETH LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20060173049-A1 | enzyme inhibitors such as 6-{2-(2-Chloro-phenyl)-5-[4-(pyrimidin-2-yloxy)-phenyl]pyrrol-1-ylmethyl}-pyridin-2-ylamine, used to treat beta-amyloid deposits and neurofibrillary tangles; Alzheimer's disease | WYETH (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204245-A1 | Amino-pyridines As Inhibitors Of Beta-secretase | BACE1, BACE2, APP | BACE1 1/4885CTSD 205/4885APP 3/4885 |
| US-20060173049-A1 | enzyme inhibitors such as 6-{2-(2-Chloro-phenyl)-5-[4-(pyrimidin-2-yloxy)-phenyl]pyrrol-1-ylmethyl}-pyridin-2-ylamine, used to treat beta-amyloid deposits and neurofibrillary tangles; Alzheimer's disease | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 126/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.